Researchers' Assessment Of 1993: Science Gained, Politics Reigned

Despite impressive lab achievements, the big news this year has sprung from the corridors of power in Washington Scientists, policy experts, administrators, and observers of the research community appear satisfied that 1993 has been a strong year in terms of research advances. They cite, for example, bold steps taken this year in gene therapies and a continuing frenzy of research on the 60-atom molecules of carbon known as buckminsterfullerenes, or buckyballs. Overall, they feel, researchers

Written byFranklin Hoke
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Overall, they feel, researchers pressed their disciplines forward on many fronts, advancing fundamental knowledge and clinical capabilities dramatically.

However, those interviewed during recent weeks by The Scientist also tend to share the opinion that the most important developments for science took place not in academic and industry labs throughout the United States, but in the nation's capital, in the halls of Congress and the agencies in whose hands lie the fate of America's research future.

Many sources agree, for example, that the most arresting single event this year--and hardly a scientific step forward--was the cancellation by Congress of the superconducting supercollider (SSC). Also cited as highly significant, if less dramatic, are the well-received science appointments that followed President Bill Clinton's inauguration in January, specifically those of Harold Varmus to head the National Institutes of Health and Neal Lane to be director of the National Science Foundation. In addition, a major ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies